Enovis Co. (NYSE:ENOV) Shares Acquired by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP lifted its holdings in shares of Enovis Co. (NYSE:ENOV - Free Report) by 919.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 333,302 shares of the company's stock after acquiring an additional 300,605 shares during the period. ExodusPoint Capital Management LP owned 0.59% of Enovis worth $14,625,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in shares of Enovis by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 5,486,130 shares of the company's stock worth $240,731,000 after purchasing an additional 75,348 shares during the last quarter. DAVENPORT & Co LLC grew its stake in Enovis by 6.0% during the 4th quarter. DAVENPORT & Co LLC now owns 2,782,341 shares of the company's stock worth $121,181,000 after buying an additional 157,216 shares during the last quarter. Royce & Associates LP increased its position in Enovis by 2.8% during the fourth quarter. Royce & Associates LP now owns 2,470,576 shares of the company's stock worth $108,409,000 after buying an additional 66,891 shares during the period. State Street Corp lifted its stake in Enovis by 4.3% in the third quarter. State Street Corp now owns 1,647,220 shares of the company's stock valued at $70,913,000 after buying an additional 68,190 shares during the last quarter. Finally, River Road Asset Management LLC boosted its holdings in shares of Enovis by 3.8% in the fourth quarter. River Road Asset Management LLC now owns 1,238,357 shares of the company's stock valued at $54,339,000 after acquiring an additional 45,762 shares during the period. Hedge funds and other institutional investors own 98.45% of the company's stock.

Enovis Stock Performance

NYSE ENOV traded up $3.63 on Wednesday, hitting $34.29. 1,444,670 shares of the company's stock were exchanged, compared to its average volume of 728,355. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The firm's 50-day moving average price is $39.40 and its two-hundred day moving average price is $42.70. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of -15.66 and a beta of 1.86. Enovis Co. has a fifty-two week low of $29.32 and a fifty-two week high of $61.92.

Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.06. The firm had revenue of $560.98 million during the quarter, compared to analysts' expectations of $555.14 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. On average, research analysts expect that Enovis Co. will post 2.79 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC restated a "buy" rating and issued a $64.00 price objective on shares of Enovis in a research note on Wednesday.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.